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ABSTRACT* 
Objective: 1) To evaluate the participation rate and 
identify the practical barriers to implementing a 
community pharmacist-led medication review 
service in francophone Switzerland and, 2) To 
assess the effectiveness of external support. 
Methods: A qualitative survey was undertaken to 
identify barriers to patient inclusion and medication 
review delivery in daily practice among all 
contactable independent pharmacists working in 
francophone Switzerland (n=78) who were 
members of a virtual chain (pharmacieplus), 
regardless of their participation in a simultaneous 
cross-sectional study. This study analyzed the 
dissemination of a medication review service 
including a prescription and drug utilization review 
with access to clinical data, a patient interview and 
a pharmaceutical report to the physicians.  In 
addition, we observed an exploratory and external 
coaching for pharmacists that we launched seven 
months after the beginning of the cross-sectional 
study.  
Results: Poor motivation on the part of pharmacists 
and difficulties communicating with physicians and 
patients were the primary obstacles identified. Lack 
of time and lack of self-confidence in administering 
the medication review process were the most 
commonly perceived practical barriers to the 
implementation of the new service. The main 
facilitators to overcome these issues may be well-
planned workflow organization techniques, 
strengthened by an adequate remuneration scheme 
and a comprehensive and practice-based training 
course that includes skill-building in 
pharmacotherapy and communication. External 
support may partially compensate for a weak 
organizational framework. 
Conclusions: To facilitate the implementation of a 
medication review service, a strong local networking 
with physicians, an effective workflow management 
and a practice- and communications-focused 
training for pharmacists and their teams seem key 
elements required. External support can be useful 
to help some pharmacists improve their service 
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management skills. Adequate remuneration seems 
necessary to encourage initial investments to 
provide such a service. Future research in this area 
may help improve the process and design of 
training programs, as well as the monitoring of 
implementation for each new pharmaceutical 
service. 
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REVISIONES DE MEDICACIÓN 
REALIZADAS POR FARMACÉUTICOS 
COMUNITARIOS EN SUIZA: ESTUDIO 
CUALITATIVO PARA EVALUAR 
BARRERAS Y FACILITADORES 
 
RESUMEN 
Objetivo: 1) Evaluar la tasa de participación e 
identificar las barreras para implantar un servicio 
de revisión de la medicación realizado por 
farmacéuticos comunitarios en la Suiza francófona 
y, 2) evaluar la efectividad del apoyo externo. 
Métodos: Todas las farmacias independientes 
contactables que trabajan en la Suiza francófona 
(n=78) que eran miembros de la cadena virtual 
(pharmacieplus), independientemente de su 
participación en un estudio transversal simultaneo 
que analizaba la diseminación del servicio de 
revisión de la medicación, que incluye la revisión 
de la prescripción y de la utilización de 
medicamentos con acceso a datos clínicos, 
entrevista a paciente y un informe de los 
farmacéuticos a los médicos. Se realizó un estudio 
cualitativo para identificar las barreras para la 
inclusión de pacientes y la provisión de revisión de 
la medicación en la práctica diaria. Además, 
analizamos un entrenador externo para 
farmacéutico que lanzamos siete meses después del 
estudio transversal.  
Resultados: La pobre motivación por parte de los 
farmacéuticos y las dificultades de comunicación 
con los médicos y los pacientes fueron los 
obstáculos principales identificados. La falta de 
tiempo y la falta de auto-confianza en la provisión 
del servicio de revisión de la medicación fueron las 
barreras prácticas más percibidas para la 
implantación del nuevo servicio. Los principales 
facilitadores para resolver estos problemas podrían 
ser las técnicas de organización de flujos de trabajo 
bien planeadas, el refuerzo por un esquema de 
remuneración adecuado, y cursos de entrenamiento 
intensivos y basados en la práctica que incluyesen 
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creación de habilidades en farmacoterapia y 
comunicación. El apoyo externo puede compensar 
parcialmente una estructura organizacional débil. 
Conclusiones: Para facilitar la implantación de un 
servicio de revisión de la medicación parecen ser 
elementos clave necesarios un contacto fuerte con 
los médicos locales, una gestión efectiva y práctica 
del flujo de trabajos y una formación centrada en 
práctica y comunicación para los farmacéuticos. El 
apoyo externo puede ser útil para ayudar a algunos 
farmacéuticos a mejorar las habilidades de gestión 
del servicio. La remuneración adecuada parece ser 
necesaria para animar a las inversiones iniciales 
para proporcionar este servicio. La investigación 
futura podría ayudar a mejorar el proceso y el 
diseño de los programas de formación, así como 
monitorizar la implementación de cada nuevo 
servicio farmacéutico. 
 
Palabras clave: Servicios de farmacia comunitaria. 
Investigación cualitativa. Suiza. 
 
 
 
 
INTRODUCTION 
For more than fifteen years, pharmacists have been 
aware that their role should go beyond simply 
selling medications, and that they should provide 
services to support the modern healthcare system.1 
However, the implementation of new community 
pharmacy services has faced several barriers.2-4  
A recent study carried out in the United States 
assessed pharmacists’ actual and perceived 
barriers to the implementation of medication therapy 
management services. The results suggested a 
difference between pharmacists who currently 
deliver services and those who are interested in 
doing so.5 The former were principally concerned 
with receiving adequate remuneration, independent 
of whether or not they were already receiving 
compensation. The second group expressed 
concerns about staff shortages and poor access to 
medical information. It is also interesting to note that 
pharmacists providing services found most barriers 
less constraining compared with those who did not 
provide services. In addition, an Australian survey 
identified facilitators of practice change in 
community pharmacies, and separately, the so-
called Seven-Factor Solution has been proposed, 
which includes: a good relationship with local 
physicians, remuneration for each pharmaceutical 
service delivered or in an implementation phase, an 
area specifically designated for services within 
pharmacies, patients’ expectations regarding such 
services, sufficiently well-trained staff, 
communication within the team, and finally external 
support/assistance with clinical aspects and/or 
implementation.6-7 
A cross-sectional study regarding the impact of a 
community pharmacist-led medication review 
service was launched in French-speaking part of 
Switzerland in 2007.8 One major aim of that study 
was to evaluate the potential contribution of this 
kind of pharmaceutical intervention into disease 
management programs. The medication review 
process chosen within this study is complex and 
known as clinical medication review.9 It is based on 
an analysis of a patient’ drugs regimen conducted 
by a community pharmacist, in order to optimize 
efficiency and safety.10 For this purpose, the 
pharmacist ought to evaluate the patient medication 
records and clinical data, and carry out a face-to-
face interview. After a systematic analysis of drug 
related problems, pharmacists sent 
recommendations to physicians who remain free to 
apply them or not. Everything is archived to monitor 
the patient and monitoring the delivery. The cross-
sectional study ran for seven months with a poor 
inclusion rate, even though several facilitators were 
provided, including remuneration, specific training, 
practical handbook, pharmacotherapeutic support, 
and basic collaborative care experiences with the 
physicians-pharmacists quality circles.11,12 This 
provided a good opportunity to assess the actual 
and perceived barriers to implement this kind of 
community pharmacy-led medication review service 
in Switzerland.  
The survey evaluated the participation rate of 
pharmacists and physicians, the process of patients 
inclusion, the effectiveness of an external support 
and identified the practical barriers to implementing 
an advanced community pharmacist-led medication 
review service 
 
METHODS  
Setting 
A cross-sectional study was conducted in French-
speaking part of Switzerland in collaboration with 90 
independent community pharmacists, all members 
of a virtual chain (pharmacieplus). Those 
pharmacists are similar to the other Swiss 
community pharmacies’ owners. The aim of this 
study was to evaluate the potential contribution of 
this kind of pharmaceutical intervention into disease 
management programs, All of the pharmacists for 
whom an e-mail address easily obtain (n=78), 
whether participating to the cross-sectional study or 
not, were invited to take part in our retrospective 
and qualitative survey that aimed to identify barriers 
and facilitators.  
Specific information and training for medication 
review service delivery 
The virtual chain financed training courses and 
engaged themselves to remunerate participating 
members with 200 Swiss Francs (130 Euros / 190 
US Dollar) per medication review. Each pharmacist 
was invited to join one of the three day-long training 
courses (scheduled between February and June 
2007), which presented practical aspects of how to 
conduct an advanced medication review service 
and explained our study in the context of daily 
pharmacy practice.  
Specific practice handbook 
An electronic, specific practice handbook (created 
using Microsoft Excel 2000) was issued to all 
participants and provided comprehensive 
information (a step-by-step description of the 
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enrolment of patients and medication review 
service) and materials (flowchart, models of letters 
addressed to patients and physicians, data 
collection forms). The whole study process is 
summarized in Table 1. 
Questionnaires 
We identified three groups of pharmacists: informed 
pharmacists who did not participate (n=60), trained 
pharmacists who volunteered to participate but who 
actually did not complete the study (n=4) and 
pharmacists who completed the entire study (n=14). 
The opinions of each of the three groups of 
pharmacists were evaluated using a specific 
questionnaire (respectively questionnaires 1, 2 and 
3). Questionnaire 1 contained an introduction letter 
that reminded participants of the purpose of the 
study and fifteen items. They concern the 
awareness and the quality of information about the 
study, an evaluation of nine barriers that had been 
identified a priori by the investigators, with a 
possibility to add more, and the interest in external 
support. Finally, five closed-form questions were 
included to characterize the pharmacy (pharmacist 
work hours, number of customers and estimation of 
the proportion of regular customers, estimation of 
the proportion of prescription drug sales). 
Questionnaire 2 contained nineteen items exploring 
experiences, and particular problems encountered 
in using the electronic quality handbook. The 
organizational framework inside of the pharmacy, 
such as the allocation of pharmacist resources, the 
tasks delegated to assistants or technicians, and 
lack of time as a major barrier to carrying out the 
study were also evaluated as well as a priori 
opinions about collaborating with physicians and 
patients before starting the study, the willingness to 
participate immediately after the training session, 
and the interest in external support. We also asked 
about remuneration and any additional barriers that 
they perceived. The same five questions as used in 
Questionnaire 1 were included to characterize the 
pharmacy. 
Questionnaire 3, composed of eighteen items, 
explored problems encountered during the study, 
perspectives on the medication review service, 
planning within the pharmacy, task assignment 
processes, the time required to participate and 
whether that represented a practical difficulty, the 
training course and the remuneration total. 
Collaboration with both physicians and patients was 
also explored. The characterization of the pharmacy 
was assessed using the same five questions as 
included in Questionnaires 1 and 2. Three additional 
questions were incorporated in this questionnaire 
when it was issued to a pharmacist who had elected 
to receive external support.  
External support 
Because of a poor inclusion rate, the investigators 
recommended external support to help certain 
pharmacists to implement the advanced medication 
review service. The support was intended primarily 
to assist pharmacists with organizing and planning 
the service. We also attempted to relieve the 
pharmacist of all technical and administrative tasks, 
in order to let the pharmacist focus on the direct 
contact with physicians and patients.  
A mentoring pharmacist visited each pharmacy at 
least three times to perform logistic steps 1.1, 1.6, 
2.1 and 2.2 (see Table 1). If requested by 
participating pharmacists, the mentoring pharmacist 
was also able to provide pharmacotherapeutic 
support to entirely or partly complete step 3. 
 
RESULTS  
Participation and inclusion rate 
Head pharmacists for whom an e-mail address was 
available were invited to complete Questionnaire 1 
(n=60), four pharmacists received Questionnaire 2 
and fourteen Questionnaire 3. Nine of these 
individuals conducted the study without help and 
five with external support. Pharmacists only 
contacted 145 (62%) of the 224 physicians who had 
at least one eligible patient. Ultimately, 61 of these 
contacted physicians agreed to participate, 
equivalent to a refusal rate of 58% (Figure 1). The 
refusal rate of contacted patients is 59% (n=134). 
Nevertheless, this represents only 18% of the total 
number of eligible patients (n=738). This difference 
arises from the loss of 250 patients due mostly to 
the lack of contacts between pharmacists and 
physicians, 178 additional patients due to 
physicians who did not participate and 84 excluding 
patients for medical reasons by their physicians. 
Barriers to implementing the medication review 
service 
The response rate and the general characteristics of 
the responders are detailed for each group of 
pharmacists in Table 2.  
Table 1. Advanced medication review process 
1. Inclusion 
1.1† Pharmaceutical records analysis according to the inclusion criteria 
1.2 Validation of patient participation by pharmacists 
1.3 Informing relevant physicians about the service (by letter, e-mail, phone or direct contact) 
1.4 Reminder contacts to physicians who failed to reply 
1.5 Confirmation of patient eligibility by checking with participating physicians 
1.6† Sending information letter to eligible patients 
1.7 Reminder contacts to patients who failed to reply 
2. Data collection 
2.1† Collect medical records from physicians 
2.2† Collect pharmaceutical records 
2.3 Schedule and complete an interview with each patient 
3. Medication review 
3.1‡ 
Analyze drug regimens on the basis of all collected 
data and consistent with evidence based medicine 
guidelines 
3.2‡ Write up recommendations to optimize treatment regimens 
3.3† Send the reports to physicians and request feedback 
†logistic support available; ‡ pharmacotherapeutic support 
available 
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Figure 1. Patient enrolment within the cross-sectional study 
 
Table 2. Demographics of survey respondents
Variable Not interested in 
participating in 
the study 
Volunteered to 
participate but 
finally withdrawn 
Completed the 
entire study in 
their pharmacy 
No. of responders 12/60 (20%) 4/4 (100%) 11/14 (79%) 
Full-time equivalent pharmacists 2.0 1.8 2.0 
No. of pharmacists conducting physicians-pharmacists 
quality circles for prescriptions† 0.9 1.7 2.6 
No. of daily customers about 250 about 200 about 200 
Proportion of prescriptions vs. OTC 70% 80% 70% 
Proportion of regular customers 70% 80% 70% 
†Physician-pharmacist quality circles: A Swiss project based on local networking between physicians and 
pharmacists to improve prescription practices (10;11) 
 
In the group of non-participants, only 12 of the 60 
pharmacists (20%) responded after we had sent 
them Questionnaire 1. Three pharmacists of the 
twelve insisted that they had been unaware of the 
study prior to receiving the survey. Of the others, 
two considered that the information was insufficient. 
Five pharmacists had heard about our program via 
the e-mail newsletter of the virtual chain. Three 
pharmacists (25%) thought they would have 
participated if they had been better informed. Of the 
barriers listed in Table 3, time and training issues 
were most often cited. Of additional barriers not 
listed in the table, one pharmacist claimed that he 
had owned his pharmacy for less than a year. Eight 
pharmacists in this group (67%) declared that they 
probably would have participated if an external 
support had been available early. 
The second group of four pharmacists, who initially 
volunteered to participate but then had second 
thoughts, discontinued the process very early, 
before contacting any physicians. Two pharmacists 
738 patients who met age, treatment and  
insurance criteria 
488 (66%) 
310 (64%) 
226 (73%) 
   92 (41%) 
85 (92%) 
250 exclusions mostly due to non 
-contacted physicians† 
178 attritions due to non-
participating physicians‡ 
84 
exclusions 
134 refusals 
7 withdrawals: 
-  1 hospitalization  
-  3 due to the withdrawal of 2 physicians 
-  3 uncountable patients
Patient participation 
validated by pharmacists 
Physicians’ general consent
Patient participation 
validated by physicians
MR
Patient 
consent 
Pharmacists (n=14)    
Pharmacists without external support         
†145 physicians contacted out of 226 (64%)‡
84 physician refusals (58%) 
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reported that the data extraction process and use of 
the quality handbook seemed complicated. With 
regards to time management, two pharmacists 
operated the study during work hours, but only as a 
second priority when they had nothing else to do. 
Two pharmacists tried to conduct the study outside 
of their normal work hours. None of these 
individuals delegated study-relevant tasks to an 
assistant or technician. Although three of these 
pharmacists considered the remuneration 
insufficient, it represented a real barrier for only one. 
All estimated that they could have reasonably spent 
one to two hours per week to deliver medication 
reviews for the proposed remuneration. Concerning 
their a priori opinions about contacting physicians, 
two thought that it would be problematic because 
physicians would find the pharmaceutical service 
too time consuming for them and would be too 
concerned about losing their patients’ trust. One 
thought this would not be a problem and the last did 
not answer. Concerning the contact of patients, only 
one pharmacist thought that this might be a 
sensitive issue. From this group, one pharmacist 
eventually agreed to participate in the study with an 
external support. 
The last group included eleven of the fourteen 
pharmacists who had implemented the medication 
review service. The biggest problem was 
collaborating with physicians. The pharmacists 
reported that physicians basically have no time for 
this kind of service and see pharmacists only as 
drug retailers, they were difficult to contact and 
convince, and physicians also had to be repeatedly 
reminded to complete their tasks (i.e. validating their 
patients’ eligibility, completing the clinical data form, 
assessing pharmaceutical recommendations). 
These pharmacists thought that an advanced 
medication review service might be useful for 
chronically-diseased patients, increasing the trust of 
physicians and patients, optimizing treatment 
regimens and helping to highlight the value of the 
pharmacist within the healthcare system. 
External support 
An external support has been proposed to fourteen 
pharmacists, including three who completed the 
training course but lacked confidence, two who had 
been identified by the investigators, and nine who 
completed Questionnaires 1 and 2. Nine of these 
individuals initially agreed to participate with the 
support but ultimately only five fully completed our 
study. Three pharmacists explained that they lacked 
confidence in contacting and collaborating with 
physicians, one failed to set appointments for 
patient interviews in time, and in another case the 
pharmacy had no eligible patients who met the 
inclusion criteria. The five pharmacists who needed 
external support did not want to complete 
medication reviews by themselves and as a result 
38 medication reviews were completed with 
assistance from the mentoring pharmacist. In the 
latter case, the average time taken to complete 
each medication review was 2.1 hours, not including 
the time spent by the mentoring pharmacist. This 
same metric was 6.4 hours for community 
pharmacists who did not receive external support.
DISCUSSION 
In the Swiss primary care setting, there is no 
organizational incentive for health professionals to 
work together. However, there is increasing 
awareness of the need to improve the safety, 
effectiveness and efficiency of the healthcare 
system. For the past 15 years, Swiss community 
pharmacists have been moving towards a more 
patient- and cognitive services-oriented approach. 
Medication review services may play a role in 
helping chronic patients to get the most out of their 
medications. 
The results of our qualitative assessment show that 
the main barrier encountered in the implementation 
of medication review services in community 
pharmacies focuses on health professionals 
themselves. Only 14 pharmacists participated 
(16%), despite the support of the virtual chain’s 
management. The majority of pharmacists seemed 
unable to invest time and resources in developing 
new services. 
Physician participation clearly depended on 
pharmacists’ self-confidence to contact them, so 
their pre-existing relationship was generally found to 
be very important. So, one-third of the eligible 
patients did not enroll because their pharmacists did 
not contact a significant proportion of the physicians 
in their neighborhood. Mutual trust should be 
strengthened to avoid the non-participation of 
physicians in the future.13 
A good approach to reinforce collaborative care at 
the local level is to conduct a physicians-
pharmacists quality circle to improve the safety and 
efficiency of the prescriptions.11,12 Ten of the 
thirteen pharmacists who completed the cross-
sectional study moderated at least one quality circle 
with physicians at the same time. 
In addition, few patients are aware of 
pharmaceutical services in general, and they do not 
know much about medication reviews led by a 
pharmacist in collaboration with their physicians. 
Even so, 41% agreed to go to an interview with their 
pharmacists, and they consented to an exchange of 
clinical data between their physicians and 
pharmacists. It seems that patients understand the 
need for coordinated monitoring of their chronic 
treatments and are not a significant barrier to the 
implementation of an advanced medication review 
service. In terms of participation issues, the need to 
increase pharmacist communication skills is an 
emerging priority, especially in the context of other 
health care providers and patients. In addition, 
information about specialized pharmaceutical 
services for the public, physicians and public health 
authorities must be improved. 
A lack of time was clearly a problem for the majority 
of pharmacists who completed the study, but even 
more so for those who did not participate (Table 4). 
Medication review services in daily practice need 
excellent workflow organization. To make time in 
their already busy schedules, pharmacists need to 
learn to better delegate tasks within their teams. To 
be efficient, delegation requires good team 
communication within the pharmacy and special 
training for staff.  
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Table 3. Pharmacists’ perceived and actual barriers to implementing the MR service 
Barriers Non-participants; n=12 
Participants who 
completed the study; 
n=11 
Difficulty finding the time 10 (83%) 6 (50%) 
Lack of staff 1 (8%) 1 (8%) 
Insufficient remuneration  0 (0%) 5 (42%) 
Weak computer skills 2 (17%) 0 (0%) 
Difficulty carrying out a MR 4 (33%) 1 (8%) 
Insufficient training 6 (50%) 6 (50%) 
Problems collaborating with physicians 2 (17%) 10 (83%) 
Problems contacting patients  1 (8%) 5 (42%) 
 
Table 4. Time spent conducting the advanced MR service 
# Invested time 
[hrs] 
No. 
MRs 
Most time 
consuming step(s) 
Invested time 
problematic? 
Task distribution 
within the team 
Planning 
1 50 3 Interactions with 
physicians; 
medication review 
no no Working hours, 
unplanned 
2 11.5 3 Patient interviews yes no Work hours, unplanned 
3† 20 5 Patient interviews yes no Work hours, unplanned 
4 40 13 Patient interviews; 
medication review 
yes no Work hours, unplanned 
and after work hours 
5 30 8 None in particular yes yes Work hours, planned and 
after work hours 
6 15 2 Training course yes yes Work hours, planned. 
7 47.5 11 Interactions with 
physicians;  Patient 
interviews 
no yes Work hours, planned 
8 40 3 Patient interviews; 
medication review 
no yes Work hours, unplanned 
9† 15 8 Patient interviews no no Work hours, unplanned 
10† 12 6 Patient interviews no no Work hours, unplanned 
11† 18 12 Patient interviews yes no Work hours unplanned. 
†Pharmacists who had received external support 
 
Fig. 2. How to overcome identified barriers to participation; enhancement, potential contribution 
of external support   
It is important to invest enough time in practical 
training for any new service to be effective as soon 
as possible. Pharmacists often lack confidence and 
may not be comfortable carrying out a medication 
review on their own and submitting their 
recommendations to physicians. Training objectives 
to implement medication review programs must 
combine skills in general high-level 
pharmacotherapy (adapted to primary care 
practice),  pharmacoeconomics and services 
Training 
- Pharmacotherapy and MR process
- Communication skills 
- Computer skills 
Self-confidence 
Collaboration 
with physicians 
Patient
inclusion 
Time 
Organizational skills 
- Management and planning 
- Skilled pharmacists 
- Task assignments across a team 
Remuneration 
- Profitability of the service 
Communication  
- With physicians and patients 
- With policymakers and media 
- Local networking 
Major facilitators Major barriers
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management as well as specific skills for medication 
reviews (e.g., patient selection, data analysis to 
identify eligible patients, conducting patient 
interviews, report writing). Computer skills are also 
critical (data management, literature reviews, 
outcomes monitoring). This constituted a major 
barrier to using some of the practical remote 
support provided by the investigators. 
The time and resource burdens are not problematic 
if the remuneration is adequate. Pharmacists did not 
generally find that the remuneration provided was 
sufficient, but the majority did not consider this a 
major problem for the pilot phase. However, time 
spent by pharmacists receiving external support is 
significantly lower (Table 4), which tends to prove 
the profitability of the service will improve with the 
acquisition of experience in this field. The benefit of 
the medication review, particularly from the point of 
view of safety, effectiveness and cost containment, 
remain to be demonstrated in order to secure 
funding from health insurance companies and the 
government. 
As Figure 2 shows, we would recommend a focus 
on training, remuneration, on-site organization and 
communication to resolve many of the issues that 
we encountered. Our results show that external 
support compensates for poor training or for poor 
on-site organization, making the remuneration and 
communication issues less important for the pilot 
phase. As found in a previous similar survey, 
pharmacists who actually participated in the study 
requested better remuneration but not the 
pharmacists who did not participate.5 
In the future, a more systematic assessment of 
barriers to providing pharmaceutical services 
among a larger population of pharmacists may 
provide more insight into the problems we identified. 
We note the relevance of the practice change 
framework used by Roberts and al. to build the 
Seven-Factor Solution.7 
 
CONCLUSIONS 
Pharmacists who have participated to a cross-
sectional study regarding the implementation of a 
community pharmacist-led advanced medication 
review service encountered several barriers, as well 
as solicited pharmacists who choose to not 
participate at all. Our qualitative survey suggests 
that this implementation is facilitated by a strong 
local networking with physicians, an effective 
workflow management and a practice- and 
communications-focused training for pharmacists 
and their teams. External support can help certain 
pharmacists improve their service-management 
skills. Adequate remuneration is necessary to allow 
initial investments but it is not the only trigger to 
provide this kind of new service. Future research in 
this area may help improve the process and design 
of training programs, as well as the monitoring of 
implementation for each new pharmaceutical 
service. 
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